These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38836510)

  • 41. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis.
    Moustafa B; Oparowski D; Testai S; Guman I; Trifan G
    J Stroke Cerebrovasc Dis; 2024 Apr; 33(4):107633. PubMed ID: 38336118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
    Zhang XL; Zhu QQ; Zhu L; Chen JZ; Chen QH; Li GN; Xie J; Kang LN; Xu B
    BMC Med; 2015 Jun; 13():123. PubMed ID: 26099511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Consensus statement of professional associations on prescribing of PCSK9-inhibitors].
    Češka R; Táborský M; Vrablík M
    Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
    Leiter LA; Zamorano JL; Bujas-Bobanovic M; Louie MJ; Lecorps G; Cannon CP; Handelsman Y
    Diabetes Obes Metab; 2017 Jul; 19(7):989-996. PubMed ID: 28206704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
    Cao YX; Liu HH; Dong QT; Li S; Li JJ
    Diabetes Obes Metab; 2018 Jun; 20(6):1391-1398. PubMed ID: 29377473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons.
    Bajaj NS; Patel N; Kalra R; Ahmad A; Venkatraman A; Arora G; Arora P
    Eur Heart J Qual Care Clin Outcomes; 2018 Apr; 4(2):132-141. PubMed ID: 29121222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.
    Stürzebecher PE; Laufs U
    Curr Opin Lipidol; 2024 Aug; 35(4):179-186. PubMed ID: 38547336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
    N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
    Rosenson RS; Jacobson TA; Preiss D; Djedjos CS; Dent R; Bridges I; Miller M
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):305-13. PubMed ID: 27240673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
    Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study.
    Seijas-Amigo J; Mauriz-Montero MJ; Suarez-Artime P; Gayoso-Rey M; Estany-Gestal A; Casas-Martínez A; González-Freire L; Rodriguez-Vazquez A; Pérez-Rodriguez N; Villaverde-Piñeiro L; Castro-Rubinos C; Espino-Faisán E; Rodríguez-Mañero M; Cordero A; González-Juanatey JR;
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):583-593. PubMed ID: 37612529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
    Handelsman Y; Lepor NE
    J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
    [No Abstract]   [Full Text] [Related]  

  • 59. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
    Brandt EJ; Benes LB; Lee L; Dayspring TD; Sorrentino M; Davidson M
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):54-61. PubMed ID: 29940784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis.
    Wang X; Wen D; Chen Y; Ma L; You C
    Cardiovasc Diabetol; 2022 Jun; 21(1):107. PubMed ID: 35706032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.